6541 — Tanvex Biopharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Tanvex Biopharma, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-2,274	-2,104	-1,543	-1,641	-2,137
Depreciation
Amortisation
Non-Cash Items	109	80.5	6.35	120	367
Unusual Items
Other Non-Cash Items
Changes in Working Capital	50.9	15.6	-93.8	-94.2	10.8
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-1,899	-1,788	-1,387	-1,334	-1,434
Capital Expenditures	-93.6	-67.5	-30.3	-96.1	-71.3
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1,913	-176	5.66	-1.27	-12.2
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	1,819	-243	-24.7	-97.4	-83.6
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	914	1,730	1,597	-123	1,080
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	797	-359	154	-1,437	-405